<DOC>
	<DOCNO>NCT00006465</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness combination chemotherapy treat patient advance solid tumor .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose dose-limiting toxicity irinotecan capecitabine give combination fix dose oxaliplatin patient advance solid tumor . - Determine pharmacokinetic parameter regimen patient . - Determine antitumor response patient treat regimen . OUTLINE : This dose-escalation study irinotecan capecitabine . Patients receive oxaliplatin IV 2 hour follow 1 hour later irinotecan IV 30 minute weekly 4 week . Patients also receive oral capecitabine twice daily day 1-5 weekly 4 week . Treatment repeat every 6 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos irinotecan capecitabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : Approximately 9-15 patient accrue study within 9-15 month .</detailed_description>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis solid tumor amenable curative surgery , radiotherapy , chemotherapy Bidimensionally measurable evaluable disease No brain metastasis primary brain tumor PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : WBC least 4,000/mm^3 Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin great 10.0 g/dL Hepatic : Bilirubin great 1.5 mg/dL AST ALT less 2 time normal Renal : Creatinine great 1.5 mg/dL Creatinine clearance great 60 mL/min Cardiovascular : No New York Heart Association class III IV heart disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study No known hypersensitivity fluorouracil PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 3 week since prior chemotherapy ( 6 week mitomycin carmustine ) recover Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 4 week since prior largefield radiotherapy recover Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>